Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP: